Fluidigm Corp
F:FLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Fluidigm Corp
Other Current Liabilities
Fluidigm Corp
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluidigm Corp
F:FLB
|
Other Current Liabilities
$67.6m
|
CAGR 3-Years
67%
|
CAGR 5-Years
38%
|
CAGR 10-Years
22%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Other Current Liabilities
$2.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
17%
|
|
|
Danaher Corp
NYSE:DHR
|
Other Current Liabilities
$1.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
|
Waters Corp
NYSE:WAT
|
Other Current Liabilities
$532.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Other Current Liabilities
$682m
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Other Current Liabilities
$2.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
14%
|
CAGR 10-Years
16%
|
|
Fluidigm Corp
Glance View
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
See Also
What is Fluidigm Corp's Other Current Liabilities?
Other Current Liabilities
67.6m
USD
Based on the financial report for Dec 31, 2025, Fluidigm Corp's Other Current Liabilities amounts to 67.6m USD.
What is Fluidigm Corp's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
22%
Over the last year, the Other Current Liabilities growth was 306%. The average annual Other Current Liabilities growth rates for Fluidigm Corp have been 67% over the past three years , 38% over the past five years , and 22% over the past ten years .
